research reports and media, page-18

Nice thread to finally come out with my research into how Paradigm all started. All IMO - backed up with what I could find.

Doing this because a) I'm bored. b) there's been some concern in this forum about our 70 year old drug (PPS) up against new frontline stem cell treatments, and that it would be great to have some comparison between PPS and new stem cell treatments. This concern was brought up due to media coverage on a Melbourne Stem Cell clinic in April(ish).

What if I was able to prove to you there already has been direct laboratory research between PPS and Mesenchymel Stem Cells? And what if I was to tell you that this research happened in a stem cell companies laboratory?

In 2010, Paul Rennie was COO of Mesoblast. Graeme Kaufman held the Strategic Development role in Mesoblast (then EVP Finance and Corporate Strategy). Peter Ghosh was a Scientific Adviser to Mesoblast. Kevin Hollingsworth was Company Secretary to Mesoblast. (all per Linkedin, company reports etc.)

In 2010, a medical paper was authored by Peter Ghosh et. al. (including Mesoblasts founder, Prof Silviu Itescu) titled:

"Pentosan polysulfate promotes proliferation and chondrogenic differentiation of adult human bone marrow-derived mesenchymal precursor cells"

It was a lab test of how PPS in different concentrations influenced MSC's in proliferation and differentiation. It's conclusion:

"This is the first study to demonstrate that PPS promotes MPC proliferation and chondrogenesis, offering new strategies for cartilage regeneration and repair in osteoarthritic joints."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875662/

My bet is - it all started here. I can't find a medical paper written by them that pits their MSC's against PPS directly (but you wouldn't would you) but what it shows was PPS was being fooled around with people closely related in work to our founders in 2010.

Now, moving forward from here I can't describe exactly how Paul Rennie, Graeme Kaufman, Peter Ghosh and Kevin Hollingsworth formed Paradigm. All I know it that MSB didn't pursue IP on PPS, whilst in 2012 Paradigm was created to ring fence patent and IP on PPS for various new treatment conditions. PAR was floated on the ASX in 2015 - they spent 3 years on patent and IP.

I also note in the EOFY report from PAR that three of the new hires are from MSB clinical/regulatory affairs - Sharon Charles, Karla Knower, Michelle Coffey.

Interesting, isn't it? It's partly why I'm betting our 70 year old drug is a winner.